Perpetual Ltd Grows Stake in Pfizer Inc. (NYSE:PFE)

Perpetual Ltd raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 136,764 shares of the biopharmaceutical company's stock after buying an additional 13,060 shares during the quarter. Perpetual Ltd's holdings in Pfizer were worth $3,466,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Sage Mountain Advisors LLC grew its holdings in Pfizer by 7.3% during the 4th quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company's stock valued at $546,000 after buying an additional 1,404 shares during the last quarter. Penobscot Investment Management Company Inc. grew its holdings in Pfizer by 2.7% during the 1st quarter. Penobscot Investment Management Company Inc. now owns 95,301 shares of the biopharmaceutical company's stock valued at $2,415,000 after buying an additional 2,527 shares during the last quarter. Brighton Jones LLC grew its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares during the last quarter. Acorn Financial Advisory Services Inc. ADV grew its holdings in Pfizer by 32.8% during the 4th quarter. Acorn Financial Advisory Services Inc. ADV now owns 9,288 shares of the biopharmaceutical company's stock valued at $246,000 after buying an additional 2,292 shares during the last quarter. Finally, Aptus Capital Advisors LLC grew its holdings in Pfizer by 124.0% during the 4th quarter. Aptus Capital Advisors LLC now owns 223,203 shares of the biopharmaceutical company's stock valued at $5,922,000 after buying an additional 123,543 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on PFE shares. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.20 on Friday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a market capitalization of $137.56 billion, a P/E ratio of 17.53, a PEG ratio of 0.88 and a beta of 0.57. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The business's fifty day moving average price is $23.46 and its 200 day moving average price is $24.85.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company posted $0.82 earnings per share. The firm's revenue was down 7.8% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.11%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.